Selonabant Shows Promise in Acute Cannabis Toxicity in Children
Anebulo Pharmaceuticals has announced positive regulatory feedback from the FDA and the closure of a capital raise. The FDA...
Axena Health Starts UI Treatment Patient Enrollment at Two Nigerian Sites
Axena Health has launched a feasibility study in Nigeria to explore a new treatment for female incontinence, combining the...
Therapeutic Blood Thinners Reduce COVID-19 Mortality
A new international study, analyzing 22 clinical trials and 11,000 patients across 21 countries, found that therapeutic doses of...
Daiichi and AstraZeneca Datopotamab Deruxtecan Application Withdrawn from EU
Daiichi Sankyo and AstraZeneca have withdrawn their EU marketing authorization application for datopotamab deruxtecan (Dato-DXd) in locally advanced or...
Exicure & GPCR Therapeutics Partner to Fuel Biotech Growth
Exicure, Inc. signed a Memorandum of Understanding with GPCR Therapeutics to acquire GPCR USA, a subsidiary specializing in G...
FDA Approves Trikafta for Additional Cystic Fibrosis Variants
The FDA has expanded the approval of Vertex Pharmaceuticals’ TRIKAFTA, a cystic fibrosis (CF) treatment, to include individuals aged...
FDA Approves Braftovi for BRAF V600E Metastatic Colorectal Cancer
The FDA granted accelerated approval to Pfizer’s BRAFTOVI (encorafenib) in combination with cetuximab and mFOLFOX6 for treating metastatic colorectal...
JCR’s JR-142 Phase III Trial Launched in Japan
JCR Pharmaceuticals has initiated a Phase III clinical trial in Japan for JR-142 (redalsomatropin alfa), a long-acting growth hormone...
Zivo Reports Efficacy vs. Avian Flu
Zivo Bioscience’s recent study with the University of Delaware demonstrates that their proprietary algal-based active ingredients can potentially reduce...
Oncodesign Reacquires Rights to OPM-201 After Positive Phase 1 Trial
Oncodesign Precision Medicine (OPM) has regained full rights to its Parkinson’s disease treatment program, OPM-201, after Servier Laboratories shifted...